Metraipolis › archive › dc_2923e89910cc
Tezepelumab in real-world US patients with severe asthma across phenotypes and underrepresented populations: the phase 4 PASSAGE study — Europe PMC PMID:42148905
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42148905
- DOI
- 10.1093/ajrccm/aamag225
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-16T13:03:46.456Z
- SHA-256 of the archived text
a7188a165d6eb8e1eaa0483ffc4accd9c9fc6253fe3650f3219e21e2c6304bd0- Stable URL of this page
https://metraipolis.com/documento/dc_2923e89910cc
How to cite
Tezepelumab in real-world US patients with severe asthma across phenotypes and underrepresented populations: the phase 4 PASSAGE study — Europe PMC PMID:42148905 — Europe PMC (en), https://europepmc.org/article/MED/42148905 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2923e89910cc (Metraipolis archive dc_2923e89910cc, sha256 a7188a165d6eb8e1eaa0483ffc4accd9c9fc6253fe3650f3219e21e2c6304bd0)
BibTeX
@misc{dc2923e89910cc,
title = {Tezepelumab in real-world US patients with severe asthma across phenotypes and underrepresented populations: the phase 4 PASSAGE study — Europe PMC PMID:42148905},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42148905},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2923e89910cc; sha256 a7188a165d6eb8e1eaa0483ffc4accd9c9fc6253fe3650f3219e21e2c6304bd0},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42148905. Agents can read the archived copy with the MCP tool read_document.